Portal de Periódicos da CAPES

Chronic chikungunya virus musculoskeletal disease: what are the underlying mechanisms?

2016; Future Medicine; Volume: 11; Issue: 3 Linguagem: Inglês

10.2217/fmb.15.147

1746-0921

Mary K. McCarthy, Thomas E. Morrison,

Autoimmune and Inflammatory Disorders Research

Future MicrobiologyVol. 11, No. 3 EditorialFree AccessChronic chikungunya virus musculoskeletal disease: what are the underlying mechanisms?Mary K McCarthy & Thomas E MorrisonMary K McCarthy Department of Immunology & Microbiology, University of Colorado School of Medicine, CO 80045, USA & Thomas E Morrison*Author for correspondence: E-mail Address: thomas.morrison@ucdenver.edu Department of Immunology & Microbiology, University of Colorado School of Medicine, CO 80045, USAPublished Online:4 Mar 2016https://doi.org/10.2217/fmb.15.147AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit First draft submitted: 1 December 2015; Accepted for publication: 4 December 2015; Published online: 4 March 2016Chikungunya virus (CHIKV) is a positive-sense enveloped RNA virus that causes large epidemics of musculoskeletal disease, including acute and chronic forms of arthritis. Starting in 2005, CHIKV re-emerged to cause outbreaks of unprecedented scale in islands of the Indian Ocean, India, South East Asia, and Europe [1–5]. In 2013, CHIKV reached the Western Hemisphere, where it is responsible for outbreaks in the Americas that have affected millions [6]. Acute CHIKV infection generally presents with fever, severe joint pain, muscle aches and rash, which subside in 7–10 days. However, up to two-thirds of infected individuals experience an incapacitating arthralgia, which often includes signs of joint inflammation and tenosynovitis that persists for months or years after the acute phase [7,8]. These persistent disease signs and symptoms cause a substantial economic burden and loss of quality of life [7]. Vaccines and antiviral agents are not currently available for CHIKV infection, and treatment is limited to managing symptoms with analgesics and anti-inflammatory drugs.Given the high percentage of patients with persistent symptoms following previous CHIKV outbreaks on other continents, it is likely that there will be a substantial population in the Americas with long-lasting pain and disability as a result of chronic CHIKV disease. Initial reports from ongoing outbreaks indicate that chronic disease is already prevalent in parts of the Americas [9–11]. Despite this growing public health concern, the underlying mechanisms of chronic musculoskeletal pain and inflammation following acute CHIKV infection are not well understood. The factors that contribute to the development of chronic CHIKV disease in individual patients are complex and may include: genetic predispositions; pre-existing arthropathy or other co-morbidities; direct virus-induced tissue damage; long-term persistence of CHIKV infection in tissues with concomitant inflammation; and activation of autoimmune responses. Thus, more research in humans and animal models is needed, as identifying effective therapies for the wide spectrum of chronic CHIKV disease manifestations will be challenging without an improved understanding of the molecular mechanisms that contribute to chronic CHIKV disease pathogenesis.Long-term studies of patients following the 2005–2006 CHIKV outbreak on La Reunion Island identified several risk factors for chronic CHIKV disease, including increased symptom severity during the acute phase, age (>45 years older), sex (female), or a pre-existing rheumatological condition [12]. Thus, in some patients there is evidence that CHIKV infection exacerbated pre-existing chronic arthropathy. However, in patients without pre-existing conditions, the cause of chronic CHIKV disease is less clear. Two main categories of chronic CHIKV disease have been described: post-CHIKV musculoskeletal disorders and post-CHIKV de novo chronic inflammatory rheumatisms (CIR) [13]. The former have been managed with analgesics, anti-inflammatory drugs, and physiotherapy. Post-CHIKV de novo CIR include rheumatoid arthritis (RA), spondyloarthritis, and undifferentiated polyarthritis and occur in patients without a history of an articular disorder prior to CHIKV infection.Evidence for autoimmune responses & viral persistence during chronic CHIKV diseaseThere is little evidence of systemic autoimmunity during acute or chronic CHIKV disease. Autoreactive CD4+ or CD8+ T cells have not been described in CHIKV patients. Serum levels of rheumatoid factor (RF), antinuclear antibodies (ANA), and anticitrullinated peptide antibodies (anti-CCP) are not appreciably elevated in patients with joint disease after acute CHIKV infection [14–17]. In studies directly comparing patients with chronic disease to those having recovered, no association between disease and ANA levels was detected [14,16]. However, it is possible that autoantigens or autoreactive lymphocytes could be present in local joint or muscle tissue and contribute to chronic CHIKV disease in these patients. In a subset of patients that have been diagnosed with post-CHIKV CIR, 30–67% are positive for ANA, RF or anti-CCP, suggesting some autoimmune involvement [13,18,19]. It is unclear whether these patients have a genetic predisposition to RA triggered by CHIKV infection, or whether post-CHIKV RA is a unique disease. Moreover, it is also unclear whether autoantibody responses in this patient subset contribute to chronic disease or simply associate with it.Assays for infectious virus, viral RNA, or viral antigen in tissues of patients with chronic CHIKV disease are not routinely performed. In a limited number of studies, CHIKV antigens and RNA have been detected in synovial or muscle tissue biopsies collected from patients with chronic musculoskeletal pain; CHIKV antigen is detected in perivascular macrophages in some cases. More definitively, experiments using nonhuman primates and mice have demonstrated that CHIKV RNA and antigen remain detectable in musculoskeletal and other tissues for months after infection [20–22]. In mice, the long-term persistence of viral RNA is associated with chronic inflammatory pathology and immune activation. Peripheral blood mononuclear cells (PBMCs) isolated from patients with chronic CHIKV disease express elevated levels of IFN-α [23]. Additionally, persistent CHIKV capsid protein and mRNA present in the synovium of a patient with severe chronic arthralgia was associated with IFN-α expression, high levels of apoptosis, and synovial tissue injury. This supports the notion that persistent virus infection or viral products, rather than an autoimmune response, promotes prolonged immune activation and injury of musculoskeletal tissue. If the long-term symptoms of CHIKV infection result from autoimmunity or a hyperactive immune response to persistent viral antigen, immunosuppression might alleviate symptoms. In contrast, if chronic CHIKV disease is a result of persistent viral replication and direct virus-induced cytotoxicity, treatment with immunosuppression might exacerbate symptoms and joint damage. There are reports that immunosuppression by methotrexate or anti-TNF-α blockade produces a positive clinical response in some patients with chronic CHIKV disease, although a subset of patients who received immunosuppressive therapy developed progressive joint or bone damage [13,18]. These data highlight the pressing need to investigate further the role of virus persistence in chronic CHIKV disease. This information is essential to inform the use of immunosuppressive agents and guide the development of new therapeutic approaches.Using animal models to fill the knowledge gapsThere is a critical need to improve models that measure and evaluate chronic CHIKV disease manifestations. Host genetic variation likely influences the outcome of CHIKV infection and the development of chronic disease. Therefore, it will be important to define mechanisms of chronic CHIKV disease pathogenesis in genetically diverse populations. These studies could take advantage of naturally occurring genetic variations in different inbred and outbred mouse strains or newly created populations of genetically diverse mice [24]. In addition, whether CHIKV infection induces autoimmunity and whether autoimmune responses contribute to chronic disease remain unanswered questions. To date, studies using animal models do not support a role for an autoimmune etiology in chronic CHIKV disease; however, as alluded above, these studies have been performed using a narrow set of genetic backgrounds. Animal models representing diverse genetic backgrounds could be employed to test whether autoantibodies or autoreactive lymphocytes are induced systemically or locally at sites of inflammation during the acute and chronic phases of CHIKV infection. If autoimmune responses were detected during CHIKV infection, demonstration that these antiself responses are arthritogenic, that disease is transferable by immune cells or serum in the absence of virus, and that autoimmune responses persist in the absence of infection would be major developments in elucidating the pathogenesis of chronic CHIKV disease. Additionally, CHIKV infection could be studied using animal models of induced, genetically manipulated, or spontaneous arthritis. If autoimmunity is present and chronic CHIKV disease is exacerbated, such results would provide evidence that: predisposition to a rheumatological disorder contributes to the development and/or severity of chronic CHIKV disease; and autoimmunity may contribute to chronic disease, at least in a subset of patients.Persistent virus infection could contribute to chronic inflammation and tissue injury. It is clear that persistent CHIKV RNA and antigen are present in musculoskeletal tissue of humans, nonhuman primates, and mice, but whether this is from ongoing low-level replication or cells harboring undegraded viral material requires further investigation. In addition, the cell types infected by CHIKV during acute and chronic infection have not been fully defined. Animal models could be used to determine the distribution of persistent CHIKV RNA and antigen in tissue, and whether CHIKV components are associated with foci of inflammatory cells. Additional experiments could be performed to determine whether the level of persistent CHIKV antigen in musculoskeletal tissue changes over time or in response to certain stimuli such as stress or additional infections. These experiments could provide evidence that unrelated or related disease exacerbations in patients with chronic disease are associated with CHIKV recrudescence in musculoskeletal tissue.ConclusionWith the re-emergence of CHIKV in the last decade, there are large numbers of individuals living with chronic musculoskeletal disease. More effort must be devoted to understanding the underlying causes of ongoing symptoms in these patients. It is not clear whether modulation of inflammation by immunosuppressive drugs will be an effective 'catch-all' strategy to limit musculoskeletal signs and symptoms in patients with chronic CHIKV disease or whether specific antiviral agents would mitigate chronic CHIKV disease. The varied spectrum of clinical presentation and response to therapy suggests that the underlying causes of ongoing symptoms may differ from patient to patient. An improved understanding of the molecular mechanisms of chronic CHIKV disease pathogenesis will inform selection and development of the most effective treatments.AcknowledgementsThe authors would like to thank MS Diamond, TS Dermody, and MT Heise for critical readings of this article.Financial & competing interests disclosureWork in the Morrison laboratory is supported by NIH-NIAID grants U19 AI109680 and R01 AI108725. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.References1 Leo YS, Chow ALP, Tan LK, Lye DC, Lin L, Ng LC. Chikungunya outbreak, Singapore, 2008. Emerg. Infect. Dis. 15, 836–837 (2009).Crossref, Medline, Google Scholar2 Kaur P, Ponniah M, Murhekar MV et al. Chikungunya outbreak, South India, 2006. Emerg. Infect. Dis. 14, 1623–1625 (2008).Crossref, Medline, Google Scholar3 Josseran L, Paquet C, Zehgnoun A et al. Chikungunya disease outbreak, Reunion Island. Emerg. Infect. Dis. 12, 1994–1995 (2006).Crossref, Medline, Google Scholar4 Depoortere E, Salmaso S, Pompa MG, Guglielmetti P, Coulombier D. Chikungunya in Europe. Lancet 371, 723 (2008).Crossref, Medline, CAS, Google Scholar5 AbuBakar S, Sam I-C, Wong P-F, MatRahim N, Hooi P-S, Roslan N. Reemergence of endemic chikungunya, Malaysia. Emerg. Infect. Dis. 13, 147–149 (2007).Crossref, Medline, Google Scholar6 Olowokure B, Francis L, Polson-Edwards K et al. The Caribbean response to chikungunya. Lancet Infect. Dis. 14, 1039–1040 (2014).Crossref, Medline, Google Scholar7 Borgherini G, Poubeau P, Jossaume A et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on Reunion Island. Clin. Infect. Dis. 47, 469–475 (2008).Crossref, Medline, Google Scholar8 Gérardin P, Fianu A, Malvy D et al. Perceived morbidity and community burden after a chikungunya outbreak: the TELECHIK survey, a population-based cohort study. BMC Med. 9, 5 (2011).Crossref, Medline, Google Scholar9 Rodríguez-Morales AJ, Calvache-Benavides CE, Giraldo-Gómez J et al. Post-chikungunya chronic arthralgia: results from a retrospective follow-up study of 131 cases in Tolima, Colombia. Travel Med. Infect. Dis. doi:10.1016/j.tmaid.2015.09.001 1–2 (2015) (Epub ahead of print).Medline, Google Scholar10 Rodríguez-Morales AJ, Villamil-Gomez W, Merlano-Espinosa M, Simone-Kleber L. Post-chikungunya chronic arthralgia: a first retrospective follow-up study of 39 cases in Colombia. Clin. Rheumatol. doi:10.1007/s10067-015-3041-8 (2015) (Epub ahead of print).Google Scholar11 Rodriguez-Morales AJ, Cardona-Ospina JA, Villamil-Gómez W, Paniz-Mondolfi AE. How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America? Rheumatol. Int. 35(12), 2091–2094 (2015).Crossref, Medline, CAS, Google Scholar12 Gérardin P, Fianu A, Michault A et al. Predictors of chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study. Arthritis Res. Amp. Ther. 15, R9 (2013).Crossref, Medline, Google Scholar13 Javelle E, Ribera A, Degasne I, Gaüzere B-A, Marimoutou C, Simon F. Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 Cases in Reunion Island from 2006–2012. PLoS Negl. Trop. Dis. 9, e0003603 (2015).Crossref, Medline, Google Scholar14 Schilte C, Staikovsky F, Couderc T et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl. Trop. Dis. 7, e2137 (2013).Crossref, Medline, Google Scholar15 Chopra A, Anuradha V, Ghorpade R, Saluja M. Acute chikungunya and persistent musculoskeletal pain following the 2006 Indian epidemic: a 2-year prospective rural community study. Epidemiol. Infect. 140, 842–850 (2011).Crossref, Medline, Google Scholar16 Venugopalan A, Ghorpade RP, Chopra A. Cytokines in acute chikungunya. PLoS ONE 9, e111305 (2014).Crossref, Medline, Google Scholar17 Miner JJ, Aw-Yeang H-X, Fox JM et al. Chikungunya viral arthritis in the United States: a mimic of seronegative rheumatoid arthritis. Arthritis Amp Rheumatol. 67(5), 1214–1220 (2015).Crossref, Medline, CAS, Google Scholar18 Bouquillard É, Combe B. A report of 21 cases of rheumatoid arthritis following chikungunya fever. A mean follow-up of two years. Joint Bone Spine 76, 654–657 (2009).Crossref, Medline, Google Scholar19 Ganu MA, Ganu AS. Post-chikungunya chronic arthritis-our experience with DMARDs over two year follow up. J. Assoc. Physicians India 59, 83–86 (2011).Medline, Google Scholar20 Poo Y-S, Rudd PA, Gardner J et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl. Trop. Dis. 8, e3354 (2014).Crossref, Medline, Google Scholar21 Labadie K, Larcher T, Joubert C et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J. Clin. Invest. 120, 894–906 (2010).Crossref, Medline, CAS, Google Scholar22 Hawman DW, Stoermer KA, Montgomery SA et al. Chronic joint disease caused by persistent chikungunya virus infection is controlled by the adaptive immune response. J. Virol. 87, 13878–13888 (2013).Crossref, Medline, CAS, Google Scholar23 Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P et al. Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J. Immunol. 184, 5914–5927 (2010).Crossref, Medline, CAS, Google Scholar24 Ferris MT, Heise MT. Quantitative genetics in the study of virus-induced disease. Adv. Virus Res. 88, 193–225 (2014).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByPost-chikungunya arthritis: a longitudinal study in a tertiary care hospital in Bangladesh8 March 2022 | Tropical Medicine and Health, Vol. 50, No. 1The clinical manifestation and the influence of age and comorbidities on long-term chikungunya disease and health-related quality of life: a 60-month prospective cohort study in Curaçao16 December 2022 | BMC Infectious Diseases, Vol. 22, No. 1Characterization and Involvement of Exosomes Originating from Chikungunya Virus-Infected Epithelial Cells in the Transmission of Infectious Viral Elements11 October 2022 | International Journal of Molecular Sciences, Vol. 23, No. 20Chikungunya Death Risk Factors in Brazil, in 2017: A case-control study7 April 2022 | PLOS ONE, Vol. 17, No. 4Emerging Tropical Viral Infections: Dengue, Chikungunya, and Zika22 June 2021Arboviruses and Muscle Disorders: From Disease to Cell Biology5 June 2020 | Viruses, Vol. 12, No. 6The Capsid Protein of Semliki Forest Virus Antagonizes RNA Interference in Mammalian CellsJournal of Virology, Vol. 94, No. 3Emerging Tropical Viral Infections: Dengue, Chikungunya, and Zika3 February 2020Tropical Diseases in Kidney Transplantation14 June 2020The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis22 March 2019 | Viruses, Vol. 11, No. 3Human CD8 T-cell activation in acute and chronic chikungunya infection3 September 2018 | Immunology, Vol. 155, No. 4Detection of chikungunya virus DNA using two-dimensional MoS2 nanosheets based disposable biosensor16 May 2018 | Scientific Reports, Vol. 8, No. 1Treatment of Chronic Chikungunya Arthritis With Methotrexate: A Systematic Review27 September 2018 | Arthritis Care & Research, Vol. 70, No. 10Chikungunya, Dengue, and Zika in Immunocompromised Hosts17 March 2018 | Current Infectious Disease Reports, Vol. 20, No. 4Ultrasonography of Hands and Wrists in the Diagnosis of Complications of Chikungunya Fever8 August 2017 | Journal of Ultrasound in Medicine, Vol. 37, No. 2Treatment of chikungunya chronic arthritis: A systematic review1 January 2018 | Revista da Associação Médica Brasileira, Vol. 64, No. 1Chikungunya virus infections: time to act, time to treatCurrent Opinion in Virology, Vol. 24The challenge of chronic chikungunyaTravel Medicine and Infectious Disease, Vol. 15 Vol. 11, No. 3 Follow us on social media for the latest updates Metrics History Published online 4 March 2016 Published in print March 2016 Information© Future Medicine LtdAcknowledgementsThe authors would like to thank MS Diamond, TS Dermody, and MT Heise for critical readings of this article.Financial & competing interests disclosureWork in the Morrison laboratory is supported by NIH-NIAID grants U19 AI109680 and R01 AI108725. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download